Orchard Therapeutics plc EBIT

The latest EBIT for ORTX is $62M as of September 2023. That compares with $-130M in the prior-year period — up 147.3% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Orchard Therapeutics plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, ORTX's EBIT moved from $-130M to $62M — a 147.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orchard Therapeutics plc's operating scale or balance-sheet position.

Against Healthcare companies, ORTX currently prints $62M for EBIT, while the sector average sits near $23B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Orchard Therapeutics plc's growth, margins, and balance sheet.

A EBIT figure of $62M for ORTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ORTX's EBIT ($62M), review year-over-year change from $-130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.